ArticleAsian journal of pharmaceutical sciences2020
Apoptosis of A549 cells by small interfering RNA targeting survivin delivery using poly-β-amino ester/guanidinylated O-carboxymethyl chitosan nanoparticles.
Article in Asian journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Separation and Characterization of Self-Assembled Nanoparticles fromAntioxidants (Basel, Switzerland) · 2026Article
- Pulmonary delivery of siRNA lipoplexes and lipid nanoparticles using a vibrating mesh nebuliser.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2026Article
- Chitosan-Based Gel Development: Extraction, Gelation Mechanisms, and Biomedical Applications.Gels (Basel, Switzerland) · 2025Review
- Polymeric nanocarriers for therapeutic gene delivery.Asian journal of pharmaceutical sciences · 2025Review
- Synthesis and characterization of poly (β-amino ester) polyplex nanocarrier with high encapsulation and uptake efficiency: impact of extracellular conditions.Nanomedicine (London, England) · 2025Article
- Gene Therapy with Chitosan Nanoparticles: Modern Formulation Strategies for Enhancing Cancer Cell Transfection.Pharmaceutics · 2024Review
- Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials.Polymers · 2023Review
- Engineering oncogene-targeted anisamide-functionalized pBAE nanoparticles as efficient lung cancer antisense therapies.RSC advances · 2023Article
- Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications.Life (Basel, Switzerland) · 2023Review
- Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Review
- Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy.Pharmaceutics · 2021Article
- Advances in Chitosan-Based Nanoparticles for Drug Delivery.International journal of molecular sciences · 2021Review
- A Review on Drug Delivery System for Tumor Therapy.Frontiers in pharmacology · 2021Review
- Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.Bioengineering (Basel, Switzerland) · 2020Review
- In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.Nanomaterials (Basel, Switzerland) · 2020Article
- Chitosan Derivatives and Their Application in Biomedicine.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene-based therapeutics has emerged as a promising approach for human cancer therapy. Among a variety of non-viral vectors, polymer vectors are particularly attractive due to their safety and multivalent groups on their surface. This study focuses on guanidinylated O-carboxymethyl chitosan (GOCMCS) along with poly-β-amino ester(PBAE) for siRNA delivery. Binding efficiency of PBAE/siRNA/GOCMCS nanoparticles were characterized by gel electrophoresis. The siRNA-loaded nanoparticles were found to be stable in the presence of RNase A, serum and BALF respectively. Fine particle fraction (FPF) which was determined by a two-stage impinger (TSI) was 57.8% ± 2.6%. The particle size and zeta potential of the nanoparticles were 153.8 ± 12.54 nm and + 12.2 ± 4.94 mV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.